摘要
探讨５－ＨＴ２ａ受体基因Ｔ１０２Ｃ多态性与氯氮平疗效之间的关系。方法随机抽取了６４例住院的精神分裂症患者和５６例难治性精神分裂症患者作研究，分别给予氯氮平≥２００ｍｇ／ｄ、≥４００ｍｇ／ｄ治疗两个月，用ＰＡＮＳＳ量表评定氯氮平疗效，用限制性片段长度多态性（ＲＦＬＰｓ）技术测定所研究对象的基因型和等位基因。结果发现氯氮平疗效好与难治性精神分裂症患者的含Ａ２的基因型及Ａ２等位基因相关联。结论５－ＨＴ２ａ受体基因Ｔ１０２Ｃ多态性在氯氮平药理作用机制中起重要的作用。
URPOSE To investigate the relationship between T102C polymorphism in the 5-HT2a receptor gene and responses to clozapine in schizophrenic patients.METHODS 64 in-patients and 56 treatment-refractory in-patients with schizophrenia were treated by clozapine (≥200mg/d, ≥400mg/d) for 2 months. The responses to clozapine were rated with positive and negative symptom scale (PANSS) and the genotypes and alleles in these patients were examined with restriction fragment length polymorphisms (RFLPs) technique.RESULTS There were strong associations between good response to clozapine and genotypes A1/A1 and A1/A2 and allele A2 in treatment-refractory schizophrenic patients.CONCLUSIONS Our findings suggest that the T102C polymorphism in the 5-HT2a receptor gene may play an important role in the pharmacological mechanicm of clozapine.
出处
《上海医科大学学报》
CSCD
1998年第4期243-246,共4页
Journal of Fudan University(Medical Science)
关键词
精神分裂症
氯氮平
5-HT2A
药物疗法
treatment-refractory schizophrenia
response to clozapine
5-HT2a receptor gene
T102C polymorphism
